Development and Validation of Interpretable Machine Learning Models for Clinically Significant Prostate Cancer Diagnosis in Patients With Lesions of PI‐RADS v2.1 Score ≥3

Background For patients with PI‐RADS v2.1 ≥ 3, prostate biopsy is strongly recommended. Due to the unsatisfactory positive rate of biopsy, improvements in clinically significant prostate cancer (csPCa) risk assessments are required. Purpose To develop and validate machine learning (ML) models based...

Full description

Saved in:
Bibliographic Details
Published inJournal of magnetic resonance imaging Vol. 60; no. 5; pp. 2130 - 2141
Main Authors Ruan, Mingjian, Liu, Yi, Yao, Kaifeng, Wang, Kexin, Fan, Yu, Wu, Shiliang, Wang, Xiaoying
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.11.2024
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background For patients with PI‐RADS v2.1 ≥ 3, prostate biopsy is strongly recommended. Due to the unsatisfactory positive rate of biopsy, improvements in clinically significant prostate cancer (csPCa) risk assessments are required. Purpose To develop and validate machine learning (ML) models based on clinical and imaging parameters for csPCa detection in patients with PI‐RADS v2.1 ≥ 3. Study Type Retrospective. Subjects One thousand eighty‐three patients with PI‐RADS v2.1 ≥ 3, randomly split into training (70%, N = 759) and validation (30%, N = 324) datasets, and 147 patients enrolled prospectively for testing. Field Strength/Sequence 3.0 T scanners/T2‐weighted fast spin echo sequence and DWI with diffusion‐weighted single‐shot gradient echo planar imaging sequence. Assessment The factors evaluated for csPCa detection were age, prostate specific antigen, prostate volume, and the diameter and location of the index lesion, PI‐RADSv2.1. Five ML models for csPCa detection were developed: logistic regression (LR), extreme gradient boosting, random forest (RF), decision tree, and support vector machines. The csPCa was defined as Gleason grade ≥2. Statistical Tests Univariable and multivariable LR analyses to identify parameters associated with csPCa. Area under the receiver operating characteristic curve (AUC), Brier score, and DeLong test were used to assess and compare the csPCa diagnostic performance with the LR model. The significance level was defined as 0.05. Results The RF model exhibited the highest AUC (0.880–0.904) and lowest Brier score (0.125–0.133) among the ML models in the validation and testing cohorts, however, there was no difference when compared to the LR model (P = 0.453 and 0.548). The sensitivity and negative predictive values in the validation and testing cohorts were 93.8%–97.6% and 82.7%–95.1%, respectively, at a threshold of 0.450 (99% sensitivity of the RF model). Data Conclusion The RF model might help for assessing the risk of csPCa and preventing overdiagnosis and unnecessary biopsy for men with PI‐RADSv2.1 ≥ 3. Evidence Level 3 Technical Efficacy Stage 2
AbstractList For patients with PI-RADS v2.1 ≥ 3, prostate biopsy is strongly recommended. Due to the unsatisfactory positive rate of biopsy, improvements in clinically significant prostate cancer (csPCa) risk assessments are required.BACKGROUNDFor patients with PI-RADS v2.1 ≥ 3, prostate biopsy is strongly recommended. Due to the unsatisfactory positive rate of biopsy, improvements in clinically significant prostate cancer (csPCa) risk assessments are required.To develop and validate machine learning (ML) models based on clinical and imaging parameters for csPCa detection in patients with PI-RADS v2.1 ≥ 3.PURPOSETo develop and validate machine learning (ML) models based on clinical and imaging parameters for csPCa detection in patients with PI-RADS v2.1 ≥ 3.Retrospective.STUDY TYPERetrospective.One thousand eighty-three patients with PI-RADS v2.1 ≥ 3, randomly split into training (70%, N = 759) and validation (30%, N = 324) datasets, and 147 patients enrolled prospectively for testing.SUBJECTSOne thousand eighty-three patients with PI-RADS v2.1 ≥ 3, randomly split into training (70%, N = 759) and validation (30%, N = 324) datasets, and 147 patients enrolled prospectively for testing.3.0 T scanners/T2-weighted fast spin echo sequence and DWI with diffusion-weighted single-shot gradient echo planar imaging sequence.FIELD STRENGTH/SEQUENCE3.0 T scanners/T2-weighted fast spin echo sequence and DWI with diffusion-weighted single-shot gradient echo planar imaging sequence.The factors evaluated for csPCa detection were age, prostate specific antigen, prostate volume, and the diameter and location of the index lesion, PI-RADSv2.1. Five ML models for csPCa detection were developed: logistic regression (LR), extreme gradient boosting, random forest (RF), decision tree, and support vector machines. The csPCa was defined as Gleason grade ≥2.ASSESSMENTThe factors evaluated for csPCa detection were age, prostate specific antigen, prostate volume, and the diameter and location of the index lesion, PI-RADSv2.1. Five ML models for csPCa detection were developed: logistic regression (LR), extreme gradient boosting, random forest (RF), decision tree, and support vector machines. The csPCa was defined as Gleason grade ≥2.Univariable and multivariable LR analyses to identify parameters associated with csPCa. Area under the receiver operating characteristic curve (AUC), Brier score, and DeLong test were used to assess and compare the csPCa diagnostic performance with the LR model. The significance level was defined as 0.05.STATISTICAL TESTSUnivariable and multivariable LR analyses to identify parameters associated with csPCa. Area under the receiver operating characteristic curve (AUC), Brier score, and DeLong test were used to assess and compare the csPCa diagnostic performance with the LR model. The significance level was defined as 0.05.The RF model exhibited the highest AUC (0.880-0.904) and lowest Brier score (0.125-0.133) among the ML models in the validation and testing cohorts, however, there was no difference when compared to the LR model (P = 0.453 and 0.548). The sensitivity and negative predictive values in the validation and testing cohorts were 93.8%-97.6% and 82.7%-95.1%, respectively, at a threshold of 0.450 (99% sensitivity of the RF model).RESULTSThe RF model exhibited the highest AUC (0.880-0.904) and lowest Brier score (0.125-0.133) among the ML models in the validation and testing cohorts, however, there was no difference when compared to the LR model (P = 0.453 and 0.548). The sensitivity and negative predictive values in the validation and testing cohorts were 93.8%-97.6% and 82.7%-95.1%, respectively, at a threshold of 0.450 (99% sensitivity of the RF model).The RF model might help for assessing the risk of csPCa and preventing overdiagnosis and unnecessary biopsy for men with PI-RADSv2.1 ≥ 3.DATA CONCLUSIONThe RF model might help for assessing the risk of csPCa and preventing overdiagnosis and unnecessary biopsy for men with PI-RADSv2.1 ≥ 3.3 TECHNICAL EFFICACY: Stage 2.EVIDENCE LEVEL3 TECHNICAL EFFICACY: Stage 2.
BackgroundFor patients with PI‐RADS v2.1 ≥ 3, prostate biopsy is strongly recommended. Due to the unsatisfactory positive rate of biopsy, improvements in clinically significant prostate cancer (csPCa) risk assessments are required.PurposeTo develop and validate machine learning (ML) models based on clinical and imaging parameters for csPCa detection in patients with PI‐RADS v2.1 ≥ 3.Study TypeRetrospective.SubjectsOne thousand eighty‐three patients with PI‐RADS v2.1 ≥ 3, randomly split into training (70%, N = 759) and validation (30%, N = 324) datasets, and 147 patients enrolled prospectively for testing.Field Strength/Sequence3.0 T scanners/T2‐weighted fast spin echo sequence and DWI with diffusion‐weighted single‐shot gradient echo planar imaging sequence.AssessmentThe factors evaluated for csPCa detection were age, prostate specific antigen, prostate volume, and the diameter and location of the index lesion, PI‐RADSv2.1. Five ML models for csPCa detection were developed: logistic regression (LR), extreme gradient boosting, random forest (RF), decision tree, and support vector machines. The csPCa was defined as Gleason grade ≥2.Statistical TestsUnivariable and multivariable LR analyses to identify parameters associated with csPCa. Area under the receiver operating characteristic curve (AUC), Brier score, and DeLong test were used to assess and compare the csPCa diagnostic performance with the LR model. The significance level was defined as 0.05.ResultsThe RF model exhibited the highest AUC (0.880–0.904) and lowest Brier score (0.125–0.133) among the ML models in the validation and testing cohorts, however, there was no difference when compared to the LR model (P = 0.453 and 0.548). The sensitivity and negative predictive values in the validation and testing cohorts were 93.8%–97.6% and 82.7%–95.1%, respectively, at a threshold of 0.450 (99% sensitivity of the RF model).Data ConclusionThe RF model might help for assessing the risk of csPCa and preventing overdiagnosis and unnecessary biopsy for men with PI‐RADSv2.1 ≥ 3.Evidence Level3Technical EfficacyStage 2
Background For patients with PI‐RADS v2.1 ≥ 3, prostate biopsy is strongly recommended. Due to the unsatisfactory positive rate of biopsy, improvements in clinically significant prostate cancer (csPCa) risk assessments are required. Purpose To develop and validate machine learning (ML) models based on clinical and imaging parameters for csPCa detection in patients with PI‐RADS v2.1 ≥ 3. Study Type Retrospective. Subjects One thousand eighty‐three patients with PI‐RADS v2.1 ≥ 3, randomly split into training (70%, N = 759) and validation (30%, N = 324) datasets, and 147 patients enrolled prospectively for testing. Field Strength/Sequence 3.0 T scanners/T2‐weighted fast spin echo sequence and DWI with diffusion‐weighted single‐shot gradient echo planar imaging sequence. Assessment The factors evaluated for csPCa detection were age, prostate specific antigen, prostate volume, and the diameter and location of the index lesion, PI‐RADSv2.1. Five ML models for csPCa detection were developed: logistic regression (LR), extreme gradient boosting, random forest (RF), decision tree, and support vector machines. The csPCa was defined as Gleason grade ≥2. Statistical Tests Univariable and multivariable LR analyses to identify parameters associated with csPCa. Area under the receiver operating characteristic curve (AUC), Brier score, and DeLong test were used to assess and compare the csPCa diagnostic performance with the LR model. The significance level was defined as 0.05. Results The RF model exhibited the highest AUC (0.880–0.904) and lowest Brier score (0.125–0.133) among the ML models in the validation and testing cohorts, however, there was no difference when compared to the LR model (P = 0.453 and 0.548). The sensitivity and negative predictive values in the validation and testing cohorts were 93.8%–97.6% and 82.7%–95.1%, respectively, at a threshold of 0.450 (99% sensitivity of the RF model). Data Conclusion The RF model might help for assessing the risk of csPCa and preventing overdiagnosis and unnecessary biopsy for men with PI‐RADSv2.1 ≥ 3. Evidence Level 3 Technical Efficacy Stage 2
For patients with PI-RADS v2.1 ≥ 3, prostate biopsy is strongly recommended. Due to the unsatisfactory positive rate of biopsy, improvements in clinically significant prostate cancer (csPCa) risk assessments are required. To develop and validate machine learning (ML) models based on clinical and imaging parameters for csPCa detection in patients with PI-RADS v2.1 ≥ 3. Retrospective. One thousand eighty-three patients with PI-RADS v2.1 ≥ 3, randomly split into training (70%, N = 759) and validation (30%, N = 324) datasets, and 147 patients enrolled prospectively for testing. 3.0 T scanners/T2-weighted fast spin echo sequence and DWI with diffusion-weighted single-shot gradient echo planar imaging sequence. The factors evaluated for csPCa detection were age, prostate specific antigen, prostate volume, and the diameter and location of the index lesion, PI-RADSv2.1. Five ML models for csPCa detection were developed: logistic regression (LR), extreme gradient boosting, random forest (RF), decision tree, and support vector machines. The csPCa was defined as Gleason grade ≥2. Univariable and multivariable LR analyses to identify parameters associated with csPCa. Area under the receiver operating characteristic curve (AUC), Brier score, and DeLong test were used to assess and compare the csPCa diagnostic performance with the LR model. The significance level was defined as 0.05. The RF model exhibited the highest AUC (0.880-0.904) and lowest Brier score (0.125-0.133) among the ML models in the validation and testing cohorts, however, there was no difference when compared to the LR model (P = 0.453 and 0.548). The sensitivity and negative predictive values in the validation and testing cohorts were 93.8%-97.6% and 82.7%-95.1%, respectively, at a threshold of 0.450 (99% sensitivity of the RF model). The RF model might help for assessing the risk of csPCa and preventing overdiagnosis and unnecessary biopsy for men with PI-RADSv2.1 ≥ 3. 3 TECHNICAL EFFICACY: Stage 2.
Author Wu, Shiliang
Wang, Xiaoying
Liu, Yi
Wang, Kexin
Yao, Kaifeng
Ruan, Mingjian
Fan, Yu
Author_xml – sequence: 1
  givenname: Mingjian
  surname: Ruan
  fullname: Ruan, Mingjian
  organization: National Urological Cancer Center of China
– sequence: 2
  givenname: Yi
  surname: Liu
  fullname: Liu, Yi
  organization: National Urological Cancer Center of China
– sequence: 3
  givenname: Kaifeng
  surname: Yao
  fullname: Yao, Kaifeng
  organization: National Urological Cancer Center of China
– sequence: 4
  givenname: Kexin
  surname: Wang
  fullname: Wang, Kexin
  organization: School of Basic Medical Sciences, Capital Medical University
– sequence: 5
  givenname: Yu
  surname: Fan
  fullname: Fan, Yu
  email: dantefanbmu@pku.edu.cn
  organization: Drug Clinical Trial Institution, Peking University First Hospital
– sequence: 6
  givenname: Shiliang
  orcidid: 0000-0002-0712-9929
  surname: Wu
  fullname: Wu, Shiliang
  email: wushiliangjsh@263.net
  organization: National Urological Cancer Center of China
– sequence: 7
  givenname: Xiaoying
  orcidid: 0000-0001-6406-0895
  surname: Wang
  fullname: Wang, Xiaoying
  email: cjr.wangxiaoying@vip.163.com
  organization: Peking University First Hospital
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38363125$$D View this record in MEDLINE/PubMed
BookMark eNp9kc1uEzEUhUeoiP7AhgdAltggpAn-zcwsq4SfoERETQVLyzNznTry2Kk9Kcqu2-54CfY8U54Ep2k3FWJ1faXvnGPdc5odOe8gy14TPCAY0w-rLpgBrWghnmUnRFCaU1EOj9IbC5aTEhfH2WmMK4xxVXHxIjtmJRsyQsVJ9mcMN2D9ugPXI-Va9F1Z06reeIe8RhPXQ1gH6FVtAc1Uc2UcoCmo4IxboplvwUakfUAja5xplLVbtDBLZ3RakuU8-NirHtBIuQYCGhu1dD6aiIxD85STciP6Yfqr5BpTatzHzie7218X5-MFuqEDghaND7C7vdvd_WYvs-da2QivHuZZdvnp4-XoSz799nkyOp_mDROFyHU7pIUWVU2roqCtxoQzxivcMuC1BqpVKzAua1wpXQk-bEvFVMkVKeumpJidZe8OtuvgrzcQe9mZ2IC1yoHfRJnOXVJecU4T-vYJuvKb4NLnJCNEYM4w44l680Bt6g5auQ6mU2ErH6tIAD4ATTpZDKBlY_r7IvqgjJUEy33bct-2vG87Sd4_kTy6_hMmB_insbD9Dym_zi4mB81feFq9vw
CitedBy_id crossref_primary_10_1002_jmri_29277
Cites_doi 10.1038/s41391-021-00417-1
10.1111/bju.15277
10.1016/j.eururo.2019.08.005
10.2307/2531595
10.1002/jmri.27692
10.1056/NEJMoa1801993
10.1001/jamanetworkopen.2023.30233
10.1016/j.eururo.2019.02.033
10.1111/bju.13465
10.1093/jnci/djj131
10.1016/j.eururo.2015.08.038
10.1007/s00330-020-07027-w
10.1038/s41585-019-0193-3
10.1890/07-0539.1
10.2196/22394
10.1007/s11548-021-02507-w
10.1016/j.eururo.2017.01.033
10.1007/s00345-020-03177-0
10.1097/PAS.0000000000000530
10.1038/s41585-019-0212-4
10.1038/aja.2012.28
10.1002/pros.21475
ContentType Journal Article
Copyright 2024 International Society for Magnetic Resonance in Medicine.
2024 International Society for Magnetic Resonance in Medicine
Copyright_xml – notice: 2024 International Society for Magnetic Resonance in Medicine.
– notice: 2024 International Society for Magnetic Resonance in Medicine
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QO
7TK
8FD
FR3
K9.
P64
7X8
DOI 10.1002/jmri.29275
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Biotechnology Research Abstracts
Neurosciences Abstracts
Technology Research Database
Engineering Research Database
ProQuest Health & Medical Complete (Alumni)
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
Engineering Research Database
Biotechnology Research Abstracts
Technology Research Database
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
ProQuest Health & Medical Complete (Alumni)

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1522-2586
EndPage 2141
ExternalDocumentID 38363125
10_1002_jmri_29275
JMRI29275
Genre researchArticle
Validation Study
Journal Article
GrantInformation_xml – fundername: National High Level Hospital Clinical Research Funding (Interdepartmental Clinical Research Project of Peking University First Hospital)
  funderid: 2022CR16; 2023IR27
– fundername: National High Level Hospital Clinical Research Funding (Interdepartmental Clinical Research Project of Peking University First Hospital)
  grantid: 2022CR16
– fundername: National High Level Hospital Clinical Research Funding (Interdepartmental Clinical Research Project of Peking University First Hospital)
  grantid: 2023IR27
GroupedDBID ---
-DZ
.3N
.GA
.GJ
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
31~
33P
3O-
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHQN
AAIPD
AAMMB
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAWTL
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABJNI
ABLJU
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCZN
ACGFO
ACGFS
ACGOF
ACIWK
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
AEFGJ
AEGXH
AEIGN
AEIMD
AENEX
AEUYR
AEYWJ
AFBPY
AFFPM
AFGKR
AFRAH
AFWVQ
AFZJQ
AGHNM
AGQPQ
AGXDD
AGYGG
AHBTC
AHMBA
AIACR
AIAGR
AIDQK
AIDYY
AITYG
AIURR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBD
EBS
EJD
EMOBN
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GNP
GODZA
H.X
HBH
HDBZQ
HF~
HGLYW
HHY
HHZ
HVGLF
HZ~
IX1
J0M
JPC
KBYEO
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M65
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RIWAO
RJQFR
ROL
RX1
RYL
SAMSI
SUPJJ
SV3
TEORI
TWZ
UB1
V2E
V8K
V9Y
W8V
W99
WBKPD
WHWMO
WIB
WIH
WIJ
WIK
WIN
WJL
WOHZO
WQJ
WVDHM
WXI
WXSBR
XG1
XV2
ZXP
ZZTAW
~IA
~WT
AAHHS
AAYXX
ACCFJ
AEEZP
AEQDE
AIWBW
AJBDE
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QO
7TK
8FD
FR3
K9.
P64
7X8
ID FETCH-LOGICAL-c3575-fd627f59b29772df01433490d3e4bfe2fad5008b09af9546d8a3a84a18bc8203
IEDL.DBID DR2
ISSN 1053-1807
1522-2586
IngestDate Fri Jul 11 07:32:19 EDT 2025
Fri Jul 25 12:05:41 EDT 2025
Thu Apr 03 07:07:58 EDT 2025
Thu Apr 24 23:06:41 EDT 2025
Tue Jul 01 03:57:02 EDT 2025
Sun Jul 06 04:45:31 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords prostate biopsy
prostate cancer
random forest
machine learning
Language English
License 2024 International Society for Magnetic Resonance in Medicine.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3575-fd627f59b29772df01433490d3e4bfe2fad5008b09af9546d8a3a84a18bc8203
Notes Mingjian Ruan and Yi Liu contributed equally to this work.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ORCID 0000-0001-6406-0895
0000-0002-0712-9929
PMID 38363125
PQID 3115043034
PQPubID 1006400
PageCount 12
ParticipantIDs proquest_miscellaneous_2928249442
proquest_journals_3115043034
pubmed_primary_38363125
crossref_citationtrail_10_1002_jmri_29275
crossref_primary_10_1002_jmri_29275
wiley_primary_10_1002_jmri_29275_JMRI29275
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate November 2024
PublicationDateYYYYMMDD 2024-11-01
PublicationDate_xml – month: 11
  year: 2024
  text: November 2024
PublicationDecade 2020
PublicationPlace Hoboken, USA
PublicationPlace_xml – name: Hoboken, USA
– name: United States
– name: Nashville
PublicationSubtitle JMRI
PublicationTitle Journal of magnetic resonance imaging
PublicationTitleAlternate J Magn Reson Imaging
PublicationYear 2024
Publisher John Wiley & Sons, Inc
Wiley Subscription Services, Inc
Publisher_xml – name: John Wiley & Sons, Inc
– name: Wiley Subscription Services, Inc
References 2021; 25
2017; 119
2021; 23
2019; 53
2023; 6
2006; 98
2019; 76
2021; 127
2020; 17
2019; 16
2020; 77
2012; 14
2012; 72
2017; 72
2021; 54
2023
2020; 30
2021
2021; 39
2018; 378
1988; 44
2016; 40
2017
2007; 88
2016; 69
e_1_2_7_6_1
e_1_2_7_5_1
Oerther B (e_1_2_7_7_1) 2021; 25
Peng T (e_1_2_7_23_1) 2021
e_1_2_7_4_1
e_1_2_7_9_1
e_1_2_7_8_1
e_1_2_7_19_1
e_1_2_7_18_1
e_1_2_7_16_1
e_1_2_7_2_1
e_1_2_7_15_1
e_1_2_7_14_1
e_1_2_7_13_1
e_1_2_7_12_1
e_1_2_7_11_1
e_1_2_7_10_1
e_1_2_7_26_1
Robinson D (e_1_2_7_3_1) 2023; 6
e_1_2_7_25_1
e_1_2_7_24_1
e_1_2_7_22_1
e_1_2_7_21_1
Mottet N (e_1_2_7_17_1) 2019; 53
e_1_2_7_20_1
References_xml – volume: 378
  start-page: 1767
  year: 2018
  end-page: 1777
  article-title: MRI‐targeted or standard biopsy for prostate‐cancer diagnosis
  publication-title: N Engl J Med
– volume: 14
  start-page: 738
  year: 2012
  end-page: 744
  article-title: External validation of the prostate cancer prevention trial and the European randomized study of screening for prostate cancer risk calculators in a Chinese cohort
  publication-title: Asian J Androl
– start-page: 2235
  year: 2021
  end-page: 2249
  article-title: Can machine learning‐based analysis of multiparameter MRI and clinical parameters improve the performance of clinically significant prostate cancer diagnosis?
  publication-title: Int J Comput Assist Radiol Surg
– volume: 72
  start-page: 721
  year: 2012
  end-page: 729
  article-title: Can the prostate risk calculator based on western population be applied to Asian population?
  publication-title: Prostate
– volume: 40
  start-page: 244
  year: 2016
  end-page: 252
  article-title: The 2014 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma definition of grading patterns and proposal for a new grading system
  publication-title: Am J Surg Pathol
– volume: 17
  start-page: 41
  year: 2020
  end-page: 61
  article-title: Multiparametric MRI for prostate cancer diagnosis: Current status and future directions
  publication-title: Nat Rev Urol
– volume: 30
  start-page: 6877
  year: 2020
  end-page: 6887
  article-title: Machine learning for the identification of clinically significant prostate cancer on MRI: A meta‐analysis
  publication-title: Eur Radiol
– volume: 16
  start-page: 391
  year: 2019
  end-page: 403
  article-title: A new era: Artificial intelligence and machine learning in prostate cancer
  publication-title: Nat Rev Urol
– volume: 119
  start-page: 225
  year: 2017
  end-page: 233
  article-title: Combination of prostate imaging reporting and data system (PI‐RADS) score and prostate‐specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients
  publication-title: BJU Int
– volume: 25
  start-page: 256
  issue: 2
  year: 2021
  end-page: 263
  article-title: Cancer detection rates of the PI‐RADSv2.1 assessment categories: systematic review and meta‐analysis on lesion level and patient level
  publication-title: Prostate Cancer Prostatic Dis
– volume: 127
  start-page: 175
  year: 2021
  end-page: 178
  article-title: Risk‐adapted biopsy decision based on prostate magnetic resonance imaging and prostate‐specific antigen density for enhanced biopsy avoidance in first prostate cancer diagnostic evaluation
  publication-title: BJU Int
– volume: 98
  start-page: 529
  year: 2006
  end-page: 534
  article-title: Assessing prostate cancer risk: Results from the prostate cancer prevention trial
  publication-title: J Natl Cancer Inst
– year: 2023
– volume: 69
  start-page: 41
  year: 2016
  end-page: 49
  article-title: Synopsis of the PI‐RADS v2 guidelines for multiparametric prostate magnetic resonance imaging and recommendations for use
  publication-title: Eur Urol
– volume: 44
  start-page: 837
  year: 1988
  end-page: 845
  article-title: Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach
  publication-title: Biometrics
– volume: 77
  start-page: 38
  year: 2020
  end-page: 52
  article-title: Recent global patterns in prostate cancer incidence and mortality rates
  publication-title: Eur Urol
– volume: 39
  start-page: 73
  year: 2021
  end-page: 80
  article-title: Comparing the prediction of prostate biopsy outcome using the Chinese Prostate Cancer Consortium (CPCC) risk calculator and the Asian adapted Rotterdam European Randomized Study of Screening for Prostate Cancer (ERSPC) risk calculator in Chinese and Europ
  publication-title: World J Urol
– volume: 76
  start-page: 340
  year: 2019
  end-page: 351
  article-title: Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2
  publication-title: Eur Urol
– year: 2017
– volume: 53
  start-page: 1
  year: 2019
  end-page: 161
  article-title: EAU‐EANM‐ESTRO‐ESUR‐SIOG guidelines on prostate cancer 2019
  publication-title: Eur Assoc Urol Guide
– volume: 23
  year: 2021
  article-title: Radiomic and genomic machine learning method performance for prostate cancer diagnosis: Systematic literature review
  publication-title: J Med Internet Res
– volume: 54
  start-page: 1466
  year: 2021
  end-page: 1473
  article-title: Magnetic resonance imaging radiomics‐based machine learning prediction of clinically significant prostate cancer in equivocal PI‐RADS 3 lesions
  publication-title: J Magn Reson Imaging
– volume: 88
  start-page: 2783
  issue: 11
  year: 2007
  end-page: 2792
  article-title: Random Forests for Classification in Ecology
  publication-title: Ecology
– volume: 6
  year: 2023
  article-title: Frequency of biopsy and tumor grade before vs after introduction of prostate magnetic resonance imaging
  publication-title: JAMA Netw Open
– volume: 72
  start-page: 45
  year: 2017
  end-page: 51
  article-title: Improving the Rotterdam European randomized study of screening for prostate cancer risk calculator for initial prostate biopsy by incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth
  publication-title: Eur Urol
– volume: 25
  start-page: 256
  issue: 2
  year: 2021
  ident: e_1_2_7_7_1
  article-title: Cancer detection rates of the PI‐RADSv2.1 assessment categories: systematic review and meta‐analysis on lesion level and patient level
  publication-title: Prostate Cancer Prostatic Dis
  doi: 10.1038/s41391-021-00417-1
– ident: e_1_2_7_6_1
  doi: 10.1111/bju.15277
– ident: e_1_2_7_16_1
  doi: 10.1016/j.eururo.2019.08.005
– ident: e_1_2_7_15_1
  doi: 10.2307/2531595
– volume: 53
  start-page: 1
  year: 2019
  ident: e_1_2_7_17_1
  article-title: EAU‐EANM‐ESTRO‐ESUR‐SIOG guidelines on prostate cancer 2019
  publication-title: Eur Assoc Urol Guide
– ident: e_1_2_7_24_1
  doi: 10.1002/jmri.27692
– ident: e_1_2_7_14_1
– ident: e_1_2_7_13_1
  doi: 10.1056/NEJMoa1801993
– volume: 6
  year: 2023
  ident: e_1_2_7_3_1
  article-title: Frequency of biopsy and tumor grade before vs after introduction of prostate magnetic resonance imaging
  publication-title: JAMA Netw Open
  doi: 10.1001/jamanetworkopen.2023.30233
– ident: e_1_2_7_4_1
  doi: 10.1016/j.eururo.2019.02.033
– ident: e_1_2_7_26_1
  doi: 10.1111/bju.13465
– ident: e_1_2_7_19_1
  doi: 10.1093/jnci/djj131
– ident: e_1_2_7_5_1
– ident: e_1_2_7_11_1
  doi: 10.1016/j.eururo.2015.08.038
– ident: e_1_2_7_9_1
  doi: 10.1007/s00330-020-07027-w
– ident: e_1_2_7_10_1
  doi: 10.1038/s41585-019-0193-3
– ident: e_1_2_7_25_1
  doi: 10.1890/07-0539.1
– ident: e_1_2_7_8_1
  doi: 10.2196/22394
– start-page: 2235
  year: 2021
  ident: e_1_2_7_23_1
  article-title: Can machine learning‐based analysis of multiparameter MRI and clinical parameters improve the performance of clinically significant prostate cancer diagnosis?
  publication-title: Int J Comput Assist Radiol Surg
  doi: 10.1007/s11548-021-02507-w
– ident: e_1_2_7_18_1
  doi: 10.1016/j.eururo.2017.01.033
– ident: e_1_2_7_20_1
  doi: 10.1007/s00345-020-03177-0
– ident: e_1_2_7_12_1
  doi: 10.1097/PAS.0000000000000530
– ident: e_1_2_7_2_1
  doi: 10.1038/s41585-019-0212-4
– ident: e_1_2_7_21_1
  doi: 10.1038/aja.2012.28
– ident: e_1_2_7_22_1
  doi: 10.1002/pros.21475
SSID ssj0009945
Score 2.4518511
Snippet Background For patients with PI‐RADS v2.1 ≥ 3, prostate biopsy is strongly recommended. Due to the unsatisfactory positive rate of biopsy, improvements in...
For patients with PI-RADS v2.1 ≥ 3, prostate biopsy is strongly recommended. Due to the unsatisfactory positive rate of biopsy, improvements in clinically...
BackgroundFor patients with PI‐RADS v2.1 ≥ 3, prostate biopsy is strongly recommended. Due to the unsatisfactory positive rate of biopsy, improvements in...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2130
SubjectTerms Aged
Biopsy
Clinical significance
Decision trees
Diffusion Magnetic Resonance Imaging - methods
Diffusion rate
Echo-Planar Imaging - methods
Field strength
Humans
Image Interpretation, Computer-Assisted - methods
Learning algorithms
Lesions
Machine Learning
Magnetic Resonance Imaging - methods
Male
Medical imaging
Middle Aged
Parameter identification
Prostate - diagnostic imaging
Prostate - pathology
prostate biopsy
Prostate cancer
Prostate-Specific Antigen - blood
Prostatic Neoplasms - diagnostic imaging
Prostatic Neoplasms - pathology
random forest
Regression analysis
Reproducibility of Results
Retrospective Studies
Risk Assessment
ROC Curve
Sensitivity analysis
Statistical analysis
Statistical tests
Support vector machines
Title Development and Validation of Interpretable Machine Learning Models for Clinically Significant Prostate Cancer Diagnosis in Patients With Lesions of PI‐RADS v2.1 Score ≥3
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjmri.29275
https://www.ncbi.nlm.nih.gov/pubmed/38363125
https://www.proquest.com/docview/3115043034
https://www.proquest.com/docview/2928249442
Volume 60
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1Lb9QwEMetqgfEhfcjtKBBcAEp26ztJLbEpWqp2kqLVrsFekGRndhtIM2izS4SnHrtjS_Bnc-0nwQ_slkKCAlukWLHiWYm-cUe_wehp0Uec8ZEGoooESEVRRxKLnmoFU54X7NcOwW-watk_zU9PI6P19CL5V4Yrw_RTbjZyHDvaxvgQjZbK9HQ92fTsoc5Tu0Oc5usZYlotNKO4txVKDb8QMI-i9JOmxRvrbpe_hr9hpiXidV9cvauo3fLm_WZJh9685ns5V9-0XH836e5ga61LArb3nluojVV30JXBu1q-230_aeMIhB1AW8MtPsaTDDRsMpXlJWCgcvKVNAKtp6ArbJWNWCgGFrx0ar6DOPypLbZScagMLQ7Tgzrwo51vSns-rS_soGyhqEXfG3gbTk7NVe1s3qNHXZ4sDj_OtreHcMn3OvD2OpwLs4vFhffyB10tPfyaGc_bCs8hDkxnBjqIsGpjrnEBkNxoa3YIKE8Koii0riLNr5jIEVGXGge06RggghGRZ_J3KALuYvW60mt7iPAURyL3NCYTjBNmXE3gVVCdIpVIUiaBujZ0tBZ3qqf2yIcVeZ1m3FmLZA5CwToSdf2o9f8-GOrzaW_ZG3cN5nVLrIqaoQG6HF32kSsXYYRtZrMG9ubmZ9eSnGA7nk_64YhjCTEMGeAnjtv-cv42eFgdOCOHvxL4w10FRsu89spN9H6bDpXDw1XzeQjFz8_AO6RIjM
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3Pb9MwFMctGBJw4TcsMMAILiClS20nsY_TxtSOdaraArtFTmKPjJCipkWC06678U9w52_qX4KfnaUMEBLcIsWOFb334m_s589D6FmehYJzGfsyiKTPZB76qUiFrxWJRFfzTFsC3-Ag6r1me4fhYZObA2dhHB-iXXCDyLDfawhwWJDeXFFDjz_Mig4RJA4voktQ0tv-UY1W9CghbI1ioyCo3-VB3NJJyeaq7_n56DeReV6z2kln97qrrFpbViHkmrzvLOZpJ_vyC8nxv9_nBrrWyFG85fznJrqgqlvo8qDZcL-Nvv-UVIRlleM3Rre7Mkx4qvEqZTEtFR7YxEyFG2brEYZCa2WNjS7GDX-0LD_jcXFUQYKSsSkewqETI3fxNnjfDO-4zL-ixkWFh475WuO3xfydeSos7NUw7LC_PPk62toZ40-k08VjQHEuT06Xp9_oHTTZfTnZ7vlNkQc_o0Yq-jqPSKxDkRKjREmugTdImQhyqlhqPEYb9zE6JQ2E1CJkUc4llZzJLk8zo17oXbRWTSu1jjAJwlBmRpDpiLCYG4-TREVUx0Tlksaxh56fWTrJGgA61OEoE4duJglYILEW8NDTtu1Hh_34Y6uNM4dJmtCvE8AXAUiNMg89aW-boIWdGFmp6aKG3tz89zJGPHTPOVo7DOU0okZ2euiFdZe_jJ_sDUZ9e3X_Xxo_Rld6k8F-st8_ePUAXSVGprnTlRtobT5bqIdGZs3TRzaYfgDrViZO
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1Nb9MwGMcfjSFNXHh_CQx4EFxASpfaTmJLXKaVah10qtoBu0yR8-IRKOnUtEhw2nU3vgR3PlM_CXacpgwQEtwixYkT-f8k_ziPfw_AkzTxBecydKUXSJfJ1HdjEQtXZSQQbcUTVRH4-vvB7mu2d-gfrsHz5VoYy4doJtxMZFTPaxPgJ6naWkFD33-c5i0iSOhfgIss8LjRdGe4gkcJUZUo1gaCum3uhQ2clGytjj3_OvrNY563rNU7p3sFjpZXa1NNPrTms7iVfPkF5Pi_t3MVLtdmFLeteq7BWlZch41-_bv9Bnz_KaUIZZHiG-3abREmnChcJSzG4wz7VVpmhjWx9RhNmbVxidoVY00fHY8_4yg_Lkx6kh5RHJglJ9rs4o7R3hQ7Nu8vLzEvcGCJryW-zWfv9FnNtF5puh30Fqdfh9udEX4irTaODIhzcXq2OPtGb8JB98XBzq5bl3hwE6qNoqvSgITKFzHRPpSkytAGKRNeSjMWa70oLR7tUmJPSCV8FqRcUsmZbPM40d6F3oL1YlJkdwCJ5_sy0XZMBYSFXOtNkiygKiRZKmkYOvB0OdBRUuPPTRWOcWTBzSQyIxBVI-DA46btiYV-_LHV5lIvUR34ZWTgRQajRpkDj5rdOmTNfxhZZJN5aY7m-quXMeLAbauzphvKaUC16XTgWaWWv_Qf7fWHvWrr7r80fggbg043etXbf3kPLhHt0ezSyk1Yn03n2X3tsWbxgyqUfgCFZiUG
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Development+and+Validation+of+Interpretable+Machine+Learning+Models+for+Clinically+Significant+Prostate+Cancer+Diagnosis+in+Patients+With+Lesions+of+PI-RADS+v2.1+Score%E2%80%89%E2%89%A53&rft.jtitle=Journal+of+magnetic+resonance+imaging&rft.au=Ruan%2C+Mingjian&rft.au=Liu%2C+Yi&rft.au=Yao%2C+Kaifeng&rft.au=Wang%2C+Kexin&rft.date=2024-11-01&rft.issn=1522-2586&rft.eissn=1522-2586&rft.volume=60&rft.issue=5&rft.spage=2130&rft_id=info:doi/10.1002%2Fjmri.29275&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1053-1807&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1053-1807&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1053-1807&client=summon